Stockholm3 evaluated for Swedish screening program

In 2022, Region Stockholm and Region Gotland (the Region) began a joint three-year project by offering organised prostate cancer testing (OPT) to all 50-year-old men living in the Region. In 2024, an evaluation of the Stockholm3 test will be made in a research project at Karolinska Institutet in collaboration with OPT.

On February 12, the first invitations were sent out to men in the Region. A total of 27,000 men born in 1974 and 1972 will be and offered Stockholm3 testing at elevated PSA values. The purpose of OPT is to make prostate cancer testing more effective and accurate, and to reach more men who do not test themselves on their own initiative. The evaluation of Stockholm3 aims to detect aggressive prostate cancer at an early stage, reduce overdiagnosis, and improve resource use in healthcare.

Since 2022, Region Värmland has used Stockholm3 in its OPT program, which is offered to all men aged 50 to 70 living in that region.

“Offering men Stockholm3 testing will provide an opportunity for earlier and more accurate diagnosis when the cancer is still curable, enable shorter lead times to treatment, and more efficient resource use in healthcare. Including Stockholm3 in the Region’s OPT program would be true a win-win for both citizens and healthcare,” says David Rosén, CEO of A3P Biomedical.

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company’s lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 90,000 men. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com

About Stockholm3

Stockholm3 is a blood test that combines protein biomarkers, genetic biomarkers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces unnecessary biopsies by 50 percent compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 90,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) “Prostate Cancer Research Award 2022”. Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers have replaced PSA with Stockholm3. Region Värmland in Sweden has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75, who benefit from a more precise test with increased sensitivity and specificity. At the same time, healthcare providers can reduce direct costs by 17 to 28 percent (1).

(1) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.